Compare Conagra Brands Inc (CAG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Viatris Inc — how do they compare? Conagra Brands Inc trades at $13.37 (market cap $6.77B), while Viatris Inc trades at $16.31 (market cap $18.99B). The key difference: Viatris Inc is far larger — about 2.8× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (9.89%). Which is the better fit depends on your goals.
| CAG | VTRS | |
|---|---|---|
Market Cap | $6.77B | $18.99B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $17.39 |
52-Week Low | $12.58 | $8.74 |
Enterprise Value | $14.05B | $31.20B |
Dividend Yield | 9.89% | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.33, up 3.62% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, missing Q2 2025 and Q1 2026 estimates but beating Q3 2025. Valuation ratios appear attractive with P/E of 10.06 and P/B of 0.84, though net income margin is negative at -0.39%. Recent news highlights upcoming Q4 earnings and dividend sustainability concerns under new leadership.
CAG presents a high-yield opportunity with a 10% dividend, but faces risks from potential dividend cuts, high debt, and revenue pressures. Analyst consensus is cautious with a $13.70 price target below current levels. Investors should weigh the defensive staple positioning against fundamental headwinds and earnings volatility for balanced risk-reward assessment.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
